DeckTherapeutics, Inc. is pioneering IV omega-3 therapeutics for prevention of acute hypoxic-ischemic injury.
Omega-3s and their natural Specialized Pro-resolving Mediator (SPM) derivatives achieve their effectiveness through simultaneous regulation of several processes which are activated by hypoxia-ischemia and cause cell death and organ injury, such as mitochondrial failure, free radical generation and apoptosis.
Our technology platform from Columbia University enables delivery of omega-3 to the brain within minutes.
Potent neuroprotection has been demonstrated in neonatal, juvenile and adult rodent models at Columbia and at four collaborating labs.
Our lead compound THDG3 is now being tested in neonatal lamb and piglet models of the serious rare pediatric disease neonatal hypoxic-ischemic encephalopathy (HIE), brain damage in newborns deprived of oxygen during labor/delivery. HIE is a main cause of cerebral palsy, epilepsy and low IQ in newborns. Our development efforts are supported by a world-class Scientific Advisory Board and clinical advisors.
Company Details
- Address
- New York, New York, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Orphan drugs, Neuroprotection, Omega-3, Neonatal, Hypoxia-ischemia, Diglyceride, EPA, DHA, Rare pediatric disease, Cerebral palsy, Epilepsy, Hypoxic-ischemic injury.
- HQ
- New York, New York
Decktherapeutics, Inc. Questions
Decktherapeutics, Inc.'s website is https://www.decktherapeutics.com/
Decktherapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/decktherapeutics-inc
Decktherapeutics, Inc.'s industry is
Biotechnology Research
Decktherapeutics, Inc.'s top competitors are
Purohit Ventures,
Prophylix As,
Zero-To-One,
Solvuu,
Nourish Creative,
Rachel Walters Collection,
Prophylix Pharma Holding As,
Taconic Biosciences,
Tins: Technology Innovation Studio,
Mirakel Technologies.
Decktherapeutics, Inc.'s categories are Biotechnology Research
